Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus

  title={Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus},
  author={Kate McKeage},
  • K. McKeage
  • Published 9 October 2014
  • Medicine, Biology
  • Drugs
Linagliptin (Trajenta®, Tradjenta®) is a dipeptidyl peptidase (DPP)-4 inhibitor approved for the treatment of adults with type 2 diabetes mellitus in several countries. A fixed-dose combination of linagliptin/metformin (Jentadueto®) is also available. This article reviews the pharmacology, therapeutic efficacy and tolerability of linagliptin in the management of type 2 diabetes, with the aim of updating its place in therapy based on recently published data. In randomized, controlled trials… 
Empagliflozin/Linagliptin: A Review in Type 2 Diabetes
Empagliflozin/linagliptin was generally well tolerated in patients with T2D, with a low risk of hypoglycaemia and no reports of exacerbations of, or hospitalizations for, heart failure during the trials.
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
  • A. Scheen
  • Medicine
    Expert opinion on drug safety
  • 2015
The good tolerance/safety profile of DPP-4 inhibitors has been largely confirmed, including in more fragile populations (elderly, renal impairment) with almost no increased risk of infection or gastrointestinal AEs, no weight gain and a minimal risk of hypoglycemia.
Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials
A systematic review of all clinical trials published by 2015 which compared the two drugs in patients with type 2 diabetes showed that the efficacy of the two drug regimens was the same, and the use of these two drugs depends on their availability and cost.
Inhibidores de dipeptidil dipeptidasa-IV: de la teoría a la práctica
This review of dipeptidyl peptidase-IV inhibitors seeks to encourage the rational use of these drugs in daily practice; this group is a new therapeutic option in monotherapy or combination therapy
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes
The fixed-dose combination of empagliflozin/linagliptin has the capacity to both effectively and safely manage diabetic patients and is expected to provide better compliance and thus improved glycaemic control coupled with a favourable safety profile.
The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies
Clinical trials evaluating the combination of SGLT2i and DPP4i show that the co-administration of these drugs in fixed-dose combinations in comparison to separate tablets does not carry additional safety concerns that each individual drug, but increases therapeutic effects, therefore, this antidiabetic combination is a safe and effective therapy for patients with T2D.
Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study
In Japanese patients with type 2 diabetes mellitus, linagliptin produced sustained reductions in HbA1c and had a safety profile consistent with the established safety profile of linag Liptin.
Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
In this PMS, linagliptin add-on therapy for Japanese T2D patients had a safety profile consistent with its known profile and HbA1c reductions over 3 years were observed.


Linagliptin: a review of its use in the management of type 2 diabetes mellitus.
Clinical data currently available indicate that linagliptin is an effective and generally well tolerated treatment option for use in patients with type 2 diabetes, including those with renal impairment for whom other antihyperglycaemia agents require dosage adjustment or are not suitable.
Linagliptin: in type 2 diabetes mellitus.
Oral linagliptin monotherapy was significantly more effective than placebo in improving glycaemic control and several parameters of pancreatic function, with placebo-corrected adjusted mean changes in glycosylated haemoglobin (HbA(1c)) levels considered clinically relevant.
Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus
Linagliptin was well tolerated and effectively inhibited plasma DPP-4 activity in patients with T2DM, producing immediate improvements in incretin levels, glucagon suppression, and glycemic control that were maintained throughout the study period.
Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial
This randomized, double-blind, parallel-group clinical trial investigated the efficacy and safety of linagliptin, a dipeptidyl peptidase-4 inhibitor, in type 2 diabetic patients with moderate to severe renal impairment and insufficient glycemic control.
Linagliptin for the treatment of type 2 diabetes.
The results of Phase III clinical trials for linagliptin, a new addition to this class of inhibitors (approved by the FDA on 2 May 2011), have been published and this agent is characterized by a pharmacokinetic and metabolic profile that may have important implications for the choice of treatment in certain patient populations.
Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.
The results of this study in African American patients with T2DM support the use of the standard 5 mg dose recommended in all populations and the overall pharmacokinetic/pharmacodynamic profile of linagliptin was comparable with that in other populations.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes, and DPP-4 inhibition with saxgliptin did not increase or decrease the rate of ischemic events, though the rates of hospitalization for heart failure was increased.